Holen Sie sich die Stockscreener-App
1.78
0.84%
-0.015
Handel nachbörslich:
1.79
0.01
+0.56%
Schlusskurs vom Vortag:
$1.795
Offen:
$1.8
24-Stunden-Volumen:
5.98M
Relative Volume:
1.28
Marktkapitalisierung:
$276.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.78M
KGV:
-1.6636
EPS:
-1.07
Netto-Cashflow:
$-75.59M
1W Leistung:
-19.46%
1M Leistung:
-22.94%
6M Leistung:
-54.59%
1J Leistung:
-73.23%
1-Tages-Spanne:
$1.65
$1.835
1-Wochen-Bereich:
$1.6012
$2.7553
52-Wochen-Spanne:
$1.15
$7.48
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Vergleichen Sie HUMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.78 | 270.68M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Trading Bots Trigger Alerts on Humacyte Inc. ActivityJuly 2025 Recap & Free High Return Stock Watch Alerts - metal.it
A Quick Look at Today's Ratings for Humacyte(HUMA.US), With a Forecast Between $3 to $14 - 富途牛牛
Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress (NASDAQ:HUMA) - Seeking Alpha
Humacyte stock price target lowered to $3.50 at TD Cowen on mixed outlook - Investing.com Canada
Humacyte stock rating reiterated at Buy by Benchmark despite revenue miss - Investing.com Canada
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright lowers Humacyte stock price target to $3 on weak sales - Investing.com Canada
Analysts Expect Breakeven For Humacyte, Inc. (NASDAQ:HUMA) Before Long - simplywall.st
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway - MSN
Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... By GuruFocus - Investing.com Canada
Humacyte Inc Navigates Challenges, Celebrates Milestones in Q2 2025 Earnings Call Highlights - AInvest
Humacyte Reports Q2 2025 Earnings and Market Expansion - TipRanks
Humacyte Reports Q2 Revenue Miss, Symvess Shows Progress in Hospital Access and Sales - AInvest
Humacyte Missed Revenue Forecasts But Expanded Symvess Access - Finimize
Humacyte: D. Boral Capital Maintains Buy, PT Raised to $25 from $20. - AInvest
Humacyte, Inc. shares fall 31.49% intraday after reporting Q2 revenue of $301,000, far below analyst expectations of $1 million. - AInvest
Humacyte stock price target lowered to $7 at BTIG on mixed Q2 results - Investing.com Canada
Humacyte's 2025 Q2 Earnings Call: Unpacking Key Contradictions on Sales, CMS Impact, and FDA Interactions - AInvest
Sitryx gets back rights to drug from Lilly deal; Humacyte is cutting costs - Endpoints News
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Humacyte Q2 2025 misses EPS and revenue targets - Investing.com UK
Transcript : Humacyte, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte Plunges 10.08% on Disappointing Earnings - AInvest
Assessing Humacyte's Long-Term Viability: A Cautionary Tale of Recurring Losses and Revenue Shortfalls - AInvest
Humacyte earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Humacyte Posts Q2 Revenue Miss - The Motley Fool
Humacyte misses Q2 revenue estimates, net loss narrows - MarketScreener
Humacyte Q2 Earnings: Military Hospitals Join 277-Strong Network as Product Sales Hit Record High - Stock Titan
Is Humacyte Inc. forming a double bottomBottom Formation Alert - mustnews.co.kr
Humacyte HUMA Q2 2025 Earnings Preview Upside Potential Driven by Product Innovations - AInvest
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - The Manila Times
Humacyte Q2 FY23: Revenue $11.1mln, down 23% YoY. - AInvest
Humacyte Q2 Earnings: Bioengineered Tissue Pioneer Reveals Latest Financial Performance - Stock Titan
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts - Yahoo Finance
What are Humacyte Inc. Equity Warrant company’s key revenue driversMassive stock growth - Jammu Links News
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
How does Humacyte Inc. Equity Warrant compare to its industry peersSuperior profit margins - Jammu Links News
Why is Humacyte Inc. stock attracting strong analyst attentionExceptional gains - Jammu Links News
What are Humacyte Inc. company’s key revenue driversAccess powerful market insights for free - Jammu Links News
What makes Humacyte Inc. stock price move sharplyUnlock powerful market trend analysis - Jammu Links News
How does Humacyte Inc. compare to its industry peersUnlock powerful market insights for success - Jammu Links News
What institutional investors are buying Humacyte Inc. stockFree Daily Trading Room Entry - Jammu Links News
Why is Humacyte Inc. Equity Warrant stock attracting strong analyst attentionMaximize gains with timely market signals - Jammu Links News
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025High-velocity capital appreciation - Jammu Links News
Is Humacyte Inc. a growth stock or a value stockDiscover the next big stock winners - Jammu Links News
Is Humacyte Inc. stock overvalued or undervaluedCapitalize on emerging investment opportunities - Jammu Links News
What are the latest earnings results for Humacyte Inc. Equity WarrantAchieve consistent returns with proven methods - jammulinksnews.com
What drives Humacyte Inc. Equity Warrant stock priceInvest confidently with proven investment plans - Jammu Links News
Should I hold or sell Humacyte Inc. stock in 2025Discover hidden gems in the stock market - Jammu Links News
Does Humacyte Inc. Equity Warrant stock perform well during market downturnsPhenomenal capital appreciation - Jammu Links News
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):